clinical trial · NCT07516899
Mass Balance Study of [14C] LPM3770164 in Healthy Participants
Huntington Disease[14C] LPM3770164
brief summary
This is a phase 1, single-center, single-dose, open-label mass-balance study to evaluate radioactive recovery rate, radioactive PK characteristics, metabolite identification, and to observe the safety in healthy male subjects of \[14C\] LPM3770164.
started
Apr 30, 2026
primary completion
Jun 30, 2026
completion
Jul 30, 2026
last updated
Apr 8, 2026
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol